Amol Akhade: What after chemotherapy plus IO in non oncogene addicted NSCLC?
Amol Akhade shared on X:
“What after chemotherapy plus IO in non oncogene addicted NSCLC?
This question is becoming more and difficult.
Another novel combination failed to improve OS against Docetaxel.
Saffron 301 trial.
Tislelizumab plus Sitravatinib in Second line NSCLC failed to improve OS against docetaxel.
Median OS of 11.5 vs 11.4 months.
3 times more deaths in Trial arm.
Trial was terminated early due Unfavorable risk benifit ration WLCC24.”
Source: Amol Akhade/X
Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors.
He also specialises in allogenic and autologous bone marrow transplant. Currently, he is a Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals.
